The short version of anti-doping testing fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Merck Millipore was the brand used by Merck Group's (not US-based Merck & Co.) global life science business until 2015 when the company re-branded. It was formed when Merck acquired the Millipore Corporation in 2010. Merck is a supplier to the life science industry. The Millipore Corporation was founded in 1954, and listed among the S&P 500 since the early 1990s, as an international biosciences company which makes micrometer pore-size filters and tests. In 2015, Merck acquired Sigma-Aldrich and merged it with Merck Millipore. In the United States and Canada, the life science business is now known as MilliporeSigma.
Pancreatic polypeptide (PP) is a polypeptide secreted by PP cells in the endocrine pancreas. It is a hormone and it regulates pancreatic secretion activities, and also impacts liver glycogen storage and gastrointestinal secretion. Its secretion may be impacted by certain endocrine tumours.
Casualty numbers have escalated significantly over time. According to a Stratfor report, the number of drug-related deaths in 2006 and 2007 (2,119 and 2,275) more than doubled to 5,207 in 2008. The number further increased substantially over the next two years, from 6,598 in 2009 to over 11,000 in 2010. According to data from the Mexican government, the death numbers are even higher: 9,616 in 2009, 15,273 in 2010, coming to a total of 47,515 killings between 2006 and January 2012. It is often not clear what deaths are part of the Mexican drug war versus general criminal homicides, and different sources give different estimates. Casualties are often measured indirectly by estimated total deaths from organized crime in Mexico. This amounts to about 115,000 people in the years 2007–2018. From 2018 to 2020, it was estimated that there were 11,400 reports of gang violence, and over 80% of the attacks targeted civilians, resulting in 13,000 related deaths during the period.
Sources: en.wikipedia.org
=== Depression === Escitalopram is among the most effective and well-tolerated antidepressants for the short-term treatment of major depressive disorder in adults. It also seems to be the safest one to give to children and adolescents. Controversy existed regarding the effectiveness of escitalopram compared with its predecessor, citalopram. The importance of this issue followed from the greater cost of escitalopram relative to the generic mixture of isomers of citalopram, prior to the expiration of the escitalopram patent in 2012, which led to charges of evergreening. Accordingly, this issue has been examined in at least 10 different systematic reviews and meta analyses. As of 2012, reviews had concluded (with caveats in some cases) that escitalopram is modestly superior to citalopram in efficacy and tolerability.
== History == The natural immunity of snakes to their own venom was observed at least as early as 1767, by Felice Fontana in his work Ricerche Fisiche sopra il Veleno della Vipera (Physical Research on the Venom of the Viper). Scottish surgeon and naturalist Patrick Russell also noted in the late 18th century that snakes were not affected by their own venom. Surgeon-Major Edward Nicholson wrote in the November 1870 Madras Medical Journal that he had witnessed a Burmese snake-catcher inoculating himself with cobra venom. However, the snake-catcher was unsure whether this was actually effective and therefore continued to treat his snakes with care. The notion of inducing immunity to venom was tested in laboratories around the world. In 1887, Dr. Henry Sewall in Michigan achieved artificial immunity to rattlesnake (Sistrurus catenatus catenatus) venom in pigeons by repeated inoculation of venom, starting with a sub-lethal dose and progressively increasing in strength until resistance developed to doses seven times the lethal dose in untreated pigeons. From 1889 to 1892, Maurice Kaufmann at the École nationale vétérinaire d'Alfort studied the effect of successive inoculations of weak doses of Vipera aspis venom on animals. Although proving that a greater resistance to low doses was possible, Kauffman was unable to achieve complete immunity against the venom at the lethal dose. The breakthrough came with the use of serum from an immunized animal to counter the effects in an unexposed animal.
These fears of subversive Peruvians were also fueled by the widely publicized kidnapping, together with the collection of a ransom of 1,000,000 dollars, of the Bolivian businessman and politician Samuel Doria Medina; a fact that was carried out by Peruvians (also classified as subversives) members of the Tupac Amaru Revolutionary Movement (MRTA). All of which were events that generated a very bad reputation for Peruvians among Bolivian society, being incited by said prejudices and stereotypes by the morbidity of the press. Despite everything, Bolivian institutions report that, in the prison population of in that country, it is not a reality that the number of Peruvian prisoners is proportionally greater than the Bolivian citizens sentenced to prison. The Commission for Human Rights and Pacification of the Congress of the Republic of Peru has come to examine multiple cases of aggressions and mistreatment in Bolivia, against Peruvian citizens, including Congresswoman Susana Díaz, after a trip to Bolivia, verified the excesses committed against Peruvian groups, coming to denounce that there is an "anti-Peruvian phobia", especially in the Desaguadero.
Sources: en.wikipedia.org
The hydrophobic effect is the observed tendency of nonpolar substances to aggregate in an aqueous solution and to be excluded by water. The word hydrophobic literally means "water-fearing", and it describes the segregation of water and nonpolar substances, which maximizes the entropy of water and minimizes the area of contact between water and nonpolar molecules. In terms of thermodynamics, the hydrophobic effect is the free energy change of water surrounding a solute. A positive free energy change of the surrounding solvent indicates hydrophobicity, whereas a negative free energy change implies hydrophilicity. The hydrophobic effect is responsible for the separation of a mixture of oil and water into its two components. It is also responsible for effects related to biology, including: cell membrane and vesicle formation, protein folding, insertion of membrane proteins into the nonpolar lipid environment and protein-small molecule associations. Hence the hydrophobic effect is essential to life. Substances for which this effect is observed are known as hydrophobes.
== Production of intracellular components == Of primary interest among the intracellular components are microbial enzymes: catalase, amylase, protease, pectinase, cellulase, hemicellulase, lipase, lactase, streptokinase and many others. Recombinant proteins, such as insulin, hepatitis B vaccine, interferon, granulocyte colony-stimulating factor, streptokinase and others are also made this way. The largest difference between this process and the others is that the cells must be ruptured (lysed) at the end of fermentation, and the environment must be manipulated to maximize the amount of the product. Furthermore, the product (typically a protein) must be separated from all of the other cellular proteins in the lysate to be purified.
Chicken McNuggets are sold in various portion sizes depending on the country of purchase. In the United States, they come in packs of 4, 6, 10, 20 and 50 (in selected stores). In some markets, including the United Kingdom, they are sold in packs of 4 (as part of a Happy Meal), 6, 9 or 20 (as a "ShareBox"). In New Zealand and Australia, they were also available in 3-packs in Happy Meals and Heart Foundation-approved "Tick healthy" meals. In Canada, Chicken McNuggets are sold in packs of 4 (as part of a Happy Meal), 6, 10, and 20. A 50-piece McNuggets meal deal has been promoted at times for special events such as the NFL's Super Bowl. They have recently been introduced by McDonald's in India, first as a part of its "Breakfast Meal" and later in the regular menu in May 2009. A halal version of the McNuggets has been sold at two franchises in Dearborn, Michigan, beginning in the early 2000s, bringing in double the average sales of regular McNuggets.
methylglyoxalase, aldoketomutase, ketone-aldehyde mutase, and (R)-S-lactoylglutathione methylglyoxal-lyase (isomerizing). In some instances, the glutathionyl moiety may be supplied by trypanothione, the analog of glutathione in parasitic protozoa such as the trypanosomes. The human gene for this enzyme is called GLO1.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.